U.S. markets closed
  • S&P Futures

    3,929.25
    +6.75 (+0.17%)
     
  • Dow Futures

    32,004.00
    +88.00 (+0.28%)
     
  • Nasdaq Futures

    13,319.75
    +17.75 (+0.13%)
     
  • Russell 2000 Futures

    2,297.70
    +12.60 (+0.55%)
     
  • Crude Oil

    63.30
    +0.08 (+0.13%)
     
  • Gold

    1,794.40
    -3.50 (-0.19%)
     
  • Silver

    28.03
    +0.17 (+0.61%)
     
  • EUR/USD

    1.2173
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4145
    +0.0003 (+0.02%)
     
  • USD/JPY

    105.9700
    +0.0880 (+0.08%)
     
  • BTC-USD

    50,290.00
    +38.00 (+0.08%)
     
  • CMC Crypto 200

    1,002.95
    -11.97 (-1.18%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,158.29
    +486.59 (+1.64%)
     

Exelixis: 4Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

ALAMEDA, Calif. (AP) _ Exelixis Inc. (EXEL) on Wednesday reported fourth-quarter net income of $28.4 million.

The Alameda, California-based company said it had profit of 9 cents per share.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 3 cents per share.

The drug developer posted revenue of $270.1 million in the period, which fell short of Street forecasts. Four analysts surveyed by Zacks expected $271.3 million.

For the year, the company reported profit of $111.8 million, or 35 cents per share. Revenue was reported as $987.5 million.

Exelixis expects full-year revenue in the range of $1.15 billion to $1.25 billion.

Exelixis shares have risen 15% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $23.03, a rise of 20% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXEL at https://www.zacks.com/ap/EXEL